Literature DB >> 10727723

Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors.

A Dekeyne1, B Denorme, S Monneyron, M J Millan.   

Abstract

The selective serotonin (5-HT) reuptake inhibitor (SSRI), citalopram (2.5 mg/kg, s.c.), reduced social interaction (SI) in rats. This action was abolished by the 5-HT(2B/2C) receptor antagonist, SB206, 553 (0.63 mg/kg, s.c.), and the 5-HT(2C) receptor antagonist, SB242, 084 (0.04 mg/kg, i.p.), but not by the 5-HT(2A) antagonist, MDL100, 907 (0.04 mg/kg, s.c.), the 5-HT(1A) antagonist, WAY100,635 (0.16 mg/kg, s.c.), or the 5-HT(3) antagonist, ondansetron (0.16 mg/kg, s. c.). These data suggest that 5-HT(2C) receptors are involved in the "anxiogenic" actions of citalopram.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727723     DOI: 10.1016/s0028-3908(99)00268-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  29 in total

1.  Chronic escitalopram treatment caused dissociative adaptation in serotonin (5-HT) 2C receptor antagonist-induced effects in REM sleep, wake and theta wave activity.

Authors:  Diána Kostyalik; Zita Kátai; Szilvia Vas; Dorottya Pap; Péter Petschner; Eszter Molnár; István Gyertyán; Lajos Kalmár; László Tóthfalusi; Gyorgy Bagdy
Journal:  Exp Brain Res       Date:  2014-01-07       Impact factor: 1.972

Review 2.  Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective.

Authors:  Ross A McDevitt; John F Neumaier
Journal:  J Chem Neuroanat       Date:  2011-05-08       Impact factor: 3.052

3.  5-HT2C receptors in the BNST are necessary for the enhancement of fear learning by selective serotonin reuptake inhibitors.

Authors:  Eliza Pelrine; Sara Diana Pasik; Leyla Bayat; Debora Goldschmiedt; Elizabeth P Bauer
Journal:  Neurobiol Learn Mem       Date:  2016-10-20       Impact factor: 2.877

4.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Authors:  Cedric Mombereau; Tamar L Gur; Jennifer Onksen; Julie A Blendy
Journal:  Int J Neuropsychopharmacol       Date:  2009-12-14       Impact factor: 5.176

5.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

6.  S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Authors:  Anne Dekeyne; Clotilde Mannoury la Cour; Alain Gobert; Mauricette Brocco; Françoise Lejeune; Florence Serres; Trevor Sharp; Annie Daszuta; Amélie Soumier; Mariusz Papp; Jean-Michel Rivet; Gunnar Flik; Thomas I Cremers; Olivier Muller; Gilbert Lavielle; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-06-04       Impact factor: 4.530

7.  Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala.

Authors:  Elizabeth I Flandreau; Chase H Bourke; Kerry J Ressler; Wylie W Vale; Charles B Nemeroff; Michael J Owens
Journal:  Psychoneuroendocrinology       Date:  2012-12-23       Impact factor: 4.905

Review 8.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

9.  5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats.

Authors:  Peter Salchner; Nicolas Singewald
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

10.  Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist.

Authors:  Nesha S Burghardt; David E A Bush; Bruce S McEwen; Joseph E LeDoux
Journal:  Biol Psychiatry       Date:  2007-05-23       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.